Effect of Triple Versus Quadruple Therapy for Treating Helicobacter Pylori Infection

Enrolling by invitation · Not applicable

Conditions studied: Dyspepsia

In brief

The Goal of this this clinical trial is to assess and compare the eradication rate of triple and quadruple therapy during treating helicobacter pylori infection among patients presented with dyspepsia. It will also assess the patient reported adverse events among two groups. H pylori infection will be confirmed by CLO (RUT) test and stool antigen test both. Standard triple therapy will be based on Esomeprazole 20 mg BD, Clarithromycin 500mg BD and Amoxicillin 1gm BD. Bismuth Quadruple therapy consists of Bismuth subcitrate 120mg QDS, Tetracycline 500mg QDS and Metronidazole 500mg TDS. Patient will be confirmed H pylori eradication 4 weeks after completion of treatment by Stool antigen test only.

Key facts

Study ID

NCT07010744

Run by

Akil Al Islam

People needed

66

Starts

2025-07-01

Expected to finish

2026-06-01

Last updated by the study team

2026-05-07

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• All dyspeptic patients aged ≥18 years.
• Patients who will provide informed written consent and agree to follow-up at 4 weeks post-treatment.

You may not qualify if…

• Patients who have received prior H. pylori eradication therapy.
• Ingestion of antibiotics or proton pump inhibitor within the prior 4 weeks. Patient who will test negative either of CLO or Stool Antigen Test or both
• Patients with known allergies or intolerance to any of the study medications.
• Patients with alarm symptoms (e.g., unexplained weight loss, persistent vomiting, dysphagia).
• Patients with a history of gastric surgery.
• Pregnant or lactating women.

Where it is running

• Dhaka Medical College — Dhaka, Bangladesh

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.